The FDA has approved AbbVie’s once-daily Parkinson’s pill Juvmo, but what does the new treatment mean for patients? Here’s ...

People living with Parkinson’s disease are hospitalized more often than other older adults, most often because of infections, falls, fractures, or other medical problems rather than Parkinson’s itself ...

Managing patients with Parkinson's disease should be viewed as part of a hospital CMO's responsibility for patient safety and quality. Hospital CMOs and their care teams need to take steps to avoid ...

Juvmo was designed to offer a reduction in motor symptoms, while reducing non-motor side effects, through its more selective ...

JUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease1 Taken once daily with or without levodopa therapy, JUVMO offers patients ...

The FDA has approved AbbVie's JUVMO (tavapadon), as the first and only selective D1/D5 receptor agonist for adults with ...

Researchers at UC San Francisco have developed a new way to improve walking for patients with Parkinson's disease using deep brain stimulation and artificial intelligence. Deep brain stimulation (DBS) ...

Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...

Forbes contributors publish independent expert analyses and insights. Michael Harley is a leading automotive industry expert and analyst. This voice experience is generated by AI. Learn more. This ...

Chinese researchers have developed a new stem cell therapy for Parkinson's disease which reportedly provides rapid improvement in symptoms for patients suffering for decades from the neurological ...

Researchers at UC San Francisco have developed a new way to improve walking for patients with Parkinson’s Disease using deep brain stimulation and artificial intelligence. Deep brain stimulation (DBS) ...